" class="no-js "lang="en-US"> Point32Health and Foundation Medicine Enter Agreement
Monday, February 26, 2024

Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer

Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, and Foundation Medicine, a pioneer in molecular profiling for cancer, have entered into a value-based agreement to make FoundationOne®CDx and FoundationOne®Liquid CDx, FDA-approved comprehensive genomic profiling (CGP) tests, available to Point32Health members with advanced cancer, including Medicaid members.

“We are proud to be a leader in innovative agreements designed to broaden access for our members to cutting-edge precision medicine technology,” said Michael Sherman, MD, MBA, MS, executive vice president and chief medical officer at Point32Health. “This collaboration with Foundation Medicine will provide our members with access to genomic information to inform use of targeted therapies, immunotherapies, and clinical trials, while avoiding treatments that are less likely to be effective. We are certain this will have a positive impact on the lives of our members living with advanced cancers, while also creating more equitable access to treatment options informed by CGP across our lines of business, regardless of age or income.”

Progress in the understanding of the molecular basis of cancer over the past two decades, coupled with new treatments which target molecular drivers in a tumor, have led to an increasing number of new precision medicine therapies for patients with advanced cancers. FoundationOne CDx and FoundationOne Liquid CDx are validated companion diagnostic tests that help oncologists match their patients to the precision medicine therapies. Use of companion diagnostics can support an evidence-based approach to treatment decision-making that can lead to better outcomes for patients with advanced cancer and help reduce waste in cancer treatment.

The goal of the agreement between Point32Health and Foundation Medicine is to extend health plan access for Foundation Medicine’s FDA-approved companion diagnostic tests to patients with advanced solid tumors through an expansion of coverage criteria. The agreement will explore utilization of CGP’s impact on patient care, health care utilization and costs, and will provide important insights to help physicians make informed decisions about personalized approaches to treatment, including clinical trial enrollment. The agreement is available to Harvard Pilgrim Health Care and Tufts Health Plan commercial members in Massachusetts, Connecticut, Rhode Island, New Hampshire and Maine, and Tufts Health Plan Medicaid members in Massachusetts and Rhode Island.

“Foundation Medicine believes every patient living with advanced cancer should benefit from comprehensive genomic information to inform their care. That’s why we’ve built a powerful portfolio that includes FDA-approved companion diagnostic tests to support oncologists in matching their patients to the right therapies,” says Mia Levy, MD, PhD, chief medical officer at Foundation Medicine. “Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and enables more people to benefit from precision cancer care. We are proud to collaborate with Point32Health and expand access to our tests.”

Eligible Harvard Pilgrim Health Care and Tufts Health Plan members with cancer should discuss the option of tumor genomic profiling with their oncologist or other treating physician.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more